ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,921 to 2,940 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Vaccine vs Placebo: serious adverse events77 of 1,253

95 of 1,251

-1.4 points

-3.4 to 0.5

2,504NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Carotid-Artery Stenting vs Carotid Endarterectomy: serious adverse events322 of 1,262

292 of 1,240

2.0 points

-1.4 to 5.3

2,502NCT00004732

Carotid Revascularization Endarterectomy Versus Stenting Trial

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography84 of 1,242

103 of 1,260

-1.4 points

-3.5 to 0.7

2,502NCT02173379

Absorb IV Randomized Controlled Trial

ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: First Occurrence of the Composite of Failed First Appropriate Clinical Shock From the Implantable Cardioverter Defibrillator (ICD) or Arrhythmic Death90 of 1,247

104 of 1,253

-1.1 points

-3.2 to 1.0

2,500NCT00800384

Shockless Implant Evaluation

ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: serious adverse events776 of 1,247

790 of 1,253

-0.8 points

-4.6 to 3.0

2,500NCT00800384

Shockless Implant Evaluation

Intervention vs Control: Proportion of Patients With Intensification of Lipid Lowering Therapy159 of 1,130

142 of 1,370

3.7 points

1.1 to 6.3

2,500NCT04394715

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

Intervention vs Control: deaths from any cause18 of 1,130

29 of 1,370

-0.5 points

-1.6 to 0.6

2,500NCT04394715

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

CVnCoV 12 μg Vaccine vs Placebo: Number of Participants Aged ≥ 61 Who Experienced a First Episode of Virologically-confirmed (RT-PCR Positive) Case of COVID-19 of Any Severity12 of 1,319

9 of 1,180

0.1 points

-0.6 to 0.9

2,499NCT04652102

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Vaccine vs Placebo: Participant Dropout Through Month 48340 of 1,251

436 of 1,245

-7.8 points

-11.4 to -4.2

2,496NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Vaccine vs Placebo: HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit75 of 1,251

68 of 1,245

0.5 points

-1.3 to 2.4

2,496NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Vaccine vs Placebo: Participant Dropout Prior to Unblinding99 of 1,251

127 of 1,245

-2.3 points

-4.6 to -0.0

2,496NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Vaccine vs Placebo: HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit49 of 1,251

46 of 1,245

0.2 points

-1.3 to 1.7

2,496NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization443 of 1,238

446 of 1,254

0.2 points

-3.5 to 4.0

2,492NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)94 of 1,236

72 of 1,255

1.9 points

-0.1 to 3.9

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)67 of 1,236

38 of 1,255

2.4 points

0.8 to 4.0

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization117 of 1,236

89 of 1,255

2.4 points

0.2 to 4.6

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR42 of 1,236

38 of 1,255

0.4 points

-1.0 to 1.8

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)138 of 1,236

107 of 1,255

2.6 points

0.3 to 5.0

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)163 of 1,236

139 of 1,255

2.1 points

-0.5 to 4.7

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)70 of 1,236

38 of 1,255

2.6 points

1.0 to 4.3

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=147"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=147

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00865566-sae",
        "title": "Vaccine vs Placebo: serious adverse events",
        "summary": "77 of 1253 against 95 of 1251; risk difference -1.4 points, 95% interval -3.4 to 0.5; NCT00865566, Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",
        "record": "/library/comparisons/NCT00865566-sae",
        "nct_id": "NCT00865566",
        "kind": "serious-adverse-events",
        "participants": 2504,
        "risk_difference": {
          "value": -0.014486734634638655,
          "lower": -0.034499130922535884,
          "upper": 0.0054039186845659705
        },
        "group_1": "77 of 1,253",
        "group_2": "95 of 1,251",
        "difference": "-1.4 points",
        "interval": "-3.4 to 0.5",
        "trial_title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men"
      },
      {
        "id": "NCT00004732-sae",
        "title": "Carotid-Artery Stenting vs Carotid Endarterectomy: serious adverse events",
        "summary": "322 of 1262 against 292 of 1240; risk difference 2.0 points, 95% interval -1.4 to 5.3; NCT00004732, Carotid Revascularization Endarterectomy Versus Stenting Trial",
        "record": "/library/comparisons/NCT00004732-sae",
        "nct_id": "NCT00004732",
        "kind": "serious-adverse-events",
        "participants": 2502,
        "risk_difference": {
          "value": 0.019666683707376953,
          "lower": -0.01406800847548393,
          "upper": 0.05331700323112988
        },
        "group_1": "322 of 1,262",
        "group_2": "292 of 1,240",
        "difference": "2.0 points",
        "interval": "-1.4 to 5.3",
        "trial_title": "Carotid Revascularization Endarterectomy Versus Stenting Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=148",
  "request_id": "lsHnA05EWViroOa2"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?